Candriam S.C.A. Sells 720 Shares of Vaxcyte, Inc. $PCVX

Candriam S.C.A. trimmed its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 0.6% during the 1st quarter, HoldingsChannel reports. The fund owned 113,390 shares of the company’s stock after selling 720 shares during the quarter. Candriam S.C.A.’s holdings in Vaxcyte were worth $4,282,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Vaxcyte in the first quarter worth $35,000. Hsbc Holdings PLC boosted its holdings in Vaxcyte by 3.1% in the first quarter. Hsbc Holdings PLC now owns 18,461 shares of the company’s stock worth $675,000 after acquiring an additional 552 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Vaxcyte by 44.4% in the first quarter. Wellington Management Group LLP now owns 6,416,930 shares of the company’s stock worth $242,303,000 after acquiring an additional 1,972,918 shares in the last quarter. Raymond James Financial Inc. boosted its holdings in Vaxcyte by 10.7% in the first quarter. Raymond James Financial Inc. now owns 293,134 shares of the company’s stock worth $11,069,000 after acquiring an additional 28,430 shares in the last quarter. Finally, Aberdeen Group plc boosted its holdings in Vaxcyte by 17.8% in the first quarter. Aberdeen Group plc now owns 264,737 shares of the company’s stock worth $9,996,000 after acquiring an additional 39,913 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Cowen restated a “buy” rating on shares of Vaxcyte in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $136.50.

Vaxcyte Price Performance

PCVX stock opened at $32.29 on Friday. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06. The business has a fifty day moving average price of $33.64 and a 200-day moving average price of $44.72. The stock has a market capitalization of $4.19 billion, a P/E ratio of -7.86 and a beta of 1.21.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.10). During the same quarter in the prior year, the firm posted ($1.10) earnings per share. As a group, analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.